EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study

Jennifer L Miller iD, Nicola Bridges, Eric I Felner, Parisa Salehi, Jack A Yanovski, David A Stevenson, Jorge Mejia-Corletto, Mohamad G Shaikh, M Jennifer Abuzzahab, Amy Fleischman, Virginia Kimonis iD, Ashley H Shoemaker und 15 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf661 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Jennifer L Miller und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, FL 32608, USA. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Hyperphagia, Diazoxide, Choline. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Soleno Therapeutics..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The hallmark condition of Prader-Willi syndrome, a rare, genetic neurobehavioral/metabolic disorder, is life-threatening hyperphagia.

Objective

We assessed the efficacy and safety of diazoxide choline extended-release (DCCR) tablets for the treatment of hyperphagia in adults and children four years of age and older with Prader-Willi syndrome.

Methods

We conducted a 16-week, randomized withdrawal study in children and adults with Prader-Willi syndrome and hyperphagia. Participants who previously completed randomized (13-week DCCR or placebo) and open-label (2.5-4.5 years DCCR) studies were randomized 1:1 to receive once-daily DCCR or placebo. The primary endpoint was Hyperphagia Questionnaire for Clinical Trials (HQ-CT) total score change from baseline to 16 weeks. Secondary endpoints included Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I); exploratory endpoints included weight and body mass index (BMI) z-score.

Results

Seventy-seven participants were randomized (DCCR:38; placebo:39). Statistically significant increases in HQ-CT from baseline to week 16 were observed with placebo vs DCCR [least square (LS) mean (standard error) change 7.6 (1.09)] with placebo and 2.6 (1.12) with DCCR; P = .0022. CGI scores favored DCCR but were not significantly changed. Consistent with the hyperphagia response, the placebo cohort gained more weight and increased their BMI z-score more than the DCCR cohort [LS mean weight difference (95% confidence interval) −1.6 kg (−3.1, −0.1)]; LS mean z-score difference was −0.09 (−0.17, −0.01). Adverse events were similar with both treatments, with no serious adverse events in the DCCR arm.

Conclusion

Continued DCCR treatment was superior to placebo for hyperphagia. DCCR appears to offer meaningful therapeutic benefits for people with Prader-Willi syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeHyperphagiaDiazoxideCholineHumansFemaleMaleDouble-Blind MethodAdultDelayed-Action PreparationsChild, PreschoolChildAdolescentYoung AdultMiddle AgedTreatment OutcomeTablets

Stichwörter der Autor:innen

Prader-Willi syndromediazoxide choline extended-release tabletshyperphagiarandomized withdrawal period study

Substanzen

Delayed-Action PreparationsDiazoxideCholineTablets

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology, University of Florida College of Medicine, Gainesville, FL 32608, USA.
  • Department of Endocrinology, Chelsea and Westminster Hospital, London SW10 9NH, UK.
  • Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
  • Endocrinology, Seattle Children's Hospital, Seattle, WA 98105, USA.
  • US Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
  • Department of Clinical Genetics, Stanford University, Palo Alto, CA 94305, USA.

ORCID-Profile: Jennifer L Miller, Virginia Kimonis, Evelien Gevers

Förderung

  • Soleno Therapeutics.

Zitieren

APA

Miller, J. L., Bridges, N., Felner, E. I., Salehi, P., Yanovski, J. A., Stevenson, D. A., Mejia-Corletto, J., Shaikh, M. G., Abuzzahab, M. J., Fleischman, A., Kimonis, V., Shoemaker, A. H., Holland, A., Bird, L. M., Obrynba, K. S., Lah, M., Littlejohn, E., Harwood, K., Shea, H., …, & Gevers, E. (2026). Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf661

Vancouver

Miller JL, Bridges N, Felner EI, Salehi P, Yanovski JA, Stevenson DA, et al. Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf661

BibTeX
@article{Miller2026,
  author = {Miller, Jennifer L and Bridges, Nicola and Felner, Eric I and Salehi, Parisa and Yanovski, Jack A and Stevenson, David A and Mejia-Corletto, Jorge and Shaikh, Mohamad G and Abuzzahab, M Jennifer and Fleischman, Amy and Kimonis, Virginia and Shoemaker, Ashley H and Holland, Anthony and Bird, Lynne M and Obrynba, Kathryn S and Lah, Melissa and Littlejohn, Elizabeth and Harwood, Katerina and Shea, Heidi and Viskochil, David and Hirano, Patricia and Yen, Kristen and Ballal, Shaila and Huang, Michael and Cowen, Neil M and Bhatnagar, Anish and Gevers, Evelien},
  title = {Diazoxide Choline Extended-release Tablets in Prader-Willi Syndrome: A Randomized, Double-blind, Withdrawal Period Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf661}
}
Kostenlos starten →